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Lansoprazole is an antituberculous prodrug
targeting cytochrome bc1
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Better antibiotics capable of killing multi-drug-resistant Mycobacterium tuberculosis are
urgently needed. Despite extensive drug discovery efforts, only a few promising candidates
are on the horizon and alternative screening protocols are required. Here, by testing a panel
of FDA-approved drugs in a host cell-based assay, we show that the blockbuster drug
lansoprazole (Prevacid), a gastric proton-pump inhibitor, has intracellular activity against
M. tuberculosis. Ex vivo pharmacokinetics and target identiﬁcation studies reveal that
lansoprazole kills M. tuberculosis by targeting its cytochrome bc1 complex through intracellular
sulfoxide reduction to lansoprazole sulﬁde. This novel class of cytochrome bc1 inhibitors is
highly active against drug-resistant clinical isolates and spares the human HþKþ-ATPase
thus providing excellent opportunities for targeting the major pathogen M. tuberculosis. Our
ﬁnding provides proof of concept for hit expansion by metabolic activation, a powerful tool for
antibiotic screens.
DOI: 10.1038/ncomms8659 OPEN
1 Global Health Institute, Ecole Polytechnique Fe´de´rale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland. 2 1st Department of Internal Medicine, University
of Cologne, D-50937 Cologne, Germany. Correspondence and requests for materials should be addressed to S.T.C. (email: stewart.cole@epﬂ.ch).
NATURE COMMUNICATIONS | 6:7659 | DOI: 10.1038/ncomms8659 | www.nature.com/naturecommunications 1
& 2015 Macmillan Publishers Limited. All rights reserved.
T
he constant spread of drug-resistant pathogens requires the
development of innovative drug-screening methods that
generate a substantial amount of lead compounds1.
The prototype of a difﬁcult-to-treat pathogen with hampered
control due to multi-drug resistance (MDR) is Mycobacterium
tuberculosis (Mtb), the causative agent of tuberculosis (TB).
Despite greatly increased efforts to identify and develop new
therapeutic agents, the TB pandemic continues to be a major
cause of morbidity and mortality worldwide. In 2013, TB was
responsible for an estimated 1.5 million deaths. In the same year,
480,000 people developed MDR-TB2. The outcome data for
patients starting MDR-TB treatment in 2011 show a success rate
of only 48%, due to lack of effective treatment regimens2. To
combat this global health problem, the rapid development of safe
drugs with new mechanisms of action is required.
In the past decade concerted screening of millions of small
molecules for growth inhibition of Mtb led to the identiﬁcation of
a few promising compounds, some of which are now in clinical
trials3. However, due to limitations in both the diversity of
chemical libraries and the seemingly limited number of druggable
targets, remarkably few truly novel hits were identiﬁed in these
basic whole-cell screens4. Host cell-based phenotypic assays that
better reﬂect the biology of the pathogen may overcome this
bottleneck by avoiding the bias of synthetic media-driven target
selection5,6. Another efﬁcient approach to ﬁght notoriously drug-
resistant pathogens such as Mtb is repurposing of existing drugs,
and their analogues, which reduces drug development costs and
saves precious time7.
When testing Food and Drug Administration (FDA)-approved
drugs in an innovative high-throughput screen selecting for
compounds that abrogate Mtb-induced cytotoxicity8, we focused
on non-antibiotic hits of clinically approved pharmacophores
active against MDR-TB. This screen identiﬁed the gastric proton-
pump inhibitor (PPI) lansoprazole (LPZ) as a compound with
intracellular anti-mycobacterial activity. PPIs, selective inhibitors
of the HþKþ -ATPase of the gastric parietal cell, are used
extensively for the treatment of acid-related disorders of the
stomach9. As non-prescription drugs, PPIs have an excellent
safety proﬁle and are among the most widely sold drugs in
the world10.
In this work, we show that LPZ is a prodrug that requires the
host’s cytoplasm for conversion into a LPZ analogue with
antituberculous activity. Successful target identiﬁcation studies
and the fact that the active compound fails to inhibit the human
gastric HþKþ -ATPase make this metabolite an attractive
lead compound for the TB drug pipeline. Our ﬁndings establish
host-cell-driven prodrug activation as an additional strategy for
successful lead identiﬁcation, which has a great potential of
broadening the spectrum of existing small-molecule libraries.
Results
LPZ inhibits growth of intracellular Mtb. We have recently
generated a host cell-based high-throughput screen that selects
for compounds that protect MRC-5 lung ﬁbroblasts from
Mtb-induced cytotoxicity8. In this assay, we infect ﬁbroblasts
with high multiplicities of infection (MOI of 10) in the presence
of screening compounds (Supplementary Fig. 1). After 72 h of
co-incubation, the majority of infected ﬁbroblasts are killed by
wild-type Mtb strains and killing can be quantiﬁed by ﬂuorescent
staining. Using this assay, we screened 1,280 FDA-approved
drugs of the Prestwick chemical library at a concentration of
10 mM thus identifying the gastric PPI LPZ as a potent hit
compound that protected ﬁbroblasts at levels comparable to
those of well-established anti-mycobacterial drugs (Fig. 1a;
Supplementary Table 1).
When conﬁrming LPZ as a hit in the primary screen, we also
tested other widely used PPIs such as omeprazole and
pantoprazole. Interestingly, these drugs failed to protect ﬁbro-
blasts at concentrations up to 50 mM (Fig. 1a). This observation
made a host-directed immunomodulatory effect leading to better
intracellular clearance of Mtb, an unlikely mechanism since most
PPIs show comparable activity on their eukaryotic target.
However, testing 5-hydroxy-LPZ, which was equally inactive at
50 mM (Fig. 1a), suggested that substitutions on the benzimida-
zole ring may account for the inactivity of these close LPZ
analogues (Supplementary Fig. 2).
Hit compound LPZ was tested for growth inhibition of
intracellular Mtb cells expressing green ﬂuorescent protein
(GFP), at different drug concentrations. LPZ reduced the Mtb-
GFP signal in a dose-dependent manner with a half-maximal
inhibitory concentration (IC50) of 1.47 mM and this corresponded
well with the protection of MRC-5 cells quantiﬁed in the same
well (Fig. 1b). To rule out a cell-line-speciﬁc effect, we performed
similar infection experiments using RAW264.7 macrophages in
which growth of intracellular bacteria was inhibited with an IC50
of 2.2 mM (Fig. 1c,d). In contrast to these results, the anti-
mycobacterial activity of LPZ in common mycobacterial broth
was 22-fold higher (IC50 of 32.8 mM) than its activity in MRC-5
cells (Supplementary Fig. 3).
LPZ is converted to LPZS intracellularly. LPZ is a relatively
unstable compound that can be modiﬁed in both enzymatic
and non-enzymatic reactions11. Its activity on the human
HþKþ -ATPase requires the prodrug LPZ to be converted to a
sulfenic acid or sulfenamide intermediate in the acidic
environment of the stomach9. We reasoned that LPZ may be
converted to an active antibiotic primarily in an intracellular
environment, thereby explaining the discrepancy between the
ex vivo and in vitro activity. Thus, we quantiﬁed intracellular
LPZ and possible metabolites over a period of 48 h using liquid
chromatography–electrospray ionization/mass spectrometry
(LC-ESI/MS) and observed a rapid intracellular decay of LPZ
and its near-quantitative conversion to a molecule of lower
mass (m/z 354.0884 gmol 1) (Fig. 2a,b; Supplementary Table 2;
Supplementary Fig. 4a). Using analogues as standards, we
identiﬁed this molecule as lansoprazole sulﬁde (LPZS), a highly
stable LPZ metabolite (Fig. 2c,d; Supplementary Fig. 4b)11. LPZS is
a precursor for LPZ production that fails to form the sulfenic acid
necessary for binding the gastric HþKþ -ATPase9,12.
Rapid decay of LPZ was also observed in broth; however, LPZS
was not the major product (Fig. 2e; Supplementary Table 2).
Assuming that LPZS has anti-mycobacterial activity, this
differential pattern of LPZ metabolism explains the better activity
of the compound during intracellular infection. This hypothesis
was conﬁrmed by testing LPZS for growth inhibition of Mtb in
broth and in intracellular assays. Strikingly, LPZS had a 71-fold
improvement of activity compared with LPZ in broth (IC50 of
0.46 mM) (Fig. 2f) and showed similar intracellular activity (IC50
of 0.59 mM) (Fig. 2g). Thus, intracellular sulfoxide reduction
converts LPZ to the potent anti-mycobacterial agent LPZS.
Having established LPZS as a compound with antibacterial
activity, we were interested in its antibiotic spectrum. Intrigu-
ingly, LPZS showed a highly Mtb-selective antibiotic proﬁle with
good activity against drug-resistant isolates (Tables 1 and 2).
Growth of several Gram-negative and Gram-positive bacteria was
not affected by LPZS (Table 1). To determine the physiological
signiﬁcance of these ﬁndings, we tested the compound in the
murine model of acute TB. Oral administration of LPZS
signiﬁcantly reduced the bacterial burden of Mtb-infected
mice (Fig. 2h; in vivo pharmacokinetic data can be found in
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Supplementary Fig. 5). There were no signs of toxicity in mice
treated with doses as high as 300mg kg 1 b.i.d., owing to the
favourable cytotoxicity proﬁle of LPZS (Supplementary Table 3).
We also performed in vitro drug combination studies with
LPZS and several ﬁrst- and second-line anti-TB drugs, where
we observed additive effects for the tested combinations
(Supplementary Table 4).
LPZS targets cytochrome b. To identify the target of LPZS, we
raised drug-resistant mutants of Mtb and identiﬁed three that
displayed stable phenotypic resistance (Fig. 3a). Whole-genome
sequencing revealed a single-nucleotide polymorphism (SNP)
that changed leucine-176 to proline in the b-subunit of the
cytochrome bc1 complex (qcrB, Rv2196) in all three mutants
(Fig. 3b). Reintroduction of this SNP into wild-type Mtb by
recombineering conﬁrmed causality (Fig. 3a, rMtb-L176P strain).
As an essential respiratory chain component, cytochrome bc1
(complex III) is required for ATP production. Consistent with
QcrB inhibition, we observed massive and rapid ATP depletion
in treated Mtb (Fig. 3c). ATP levels of the L176P mutant strain
were hardly affected by LPZS treatment (Supplementary Fig. 6a).
To provide further proof for LPZS targeting cytochrome bc1, we
measured ADP levels in LPZS-treated and untreated bacteria,
which allowed us to calculate the ADP/ATP ratio. In untreated
wild-type Mtb, this ratio was 3.5, LPZS treatment led to a 7-fold
increase of intracellular ADP levels upon treatment and an ADP/
ATP ratio of 25.8. Most importantly, this effect was not observed
when the LPZS-resistant L176P mutant strain was tested
(Supplementary Fig. 6b). Thus we provide strong evidence
that QcrB is indeed the target protein of the LPZ metabolite
LPZS, which is a highly unexpected ﬁnding since the gastric
HþKþ -ATPase and cytochrome bc1 are structurally unrelated
protein complexes.
LPZS represents a novel class of QcrB inhibitors. QcrB is an
emerging and highly vulnerable drug target of Mtb. Recently
identiﬁed imidazopyridine amides (IPAs) display potent in vitro
and in vivo activity against Mtb13,14. Many data for LPZS are
similar to ﬁndings obtained with IPA compounds. Both classes
share a highlyMtb-selective activity proﬁle; they are bacteriostatic
in broth and inactive against streptomycin-starved 18b (SS18b),
a viable but conditionally non-replicating strain of Mtb
0
5
10
15
Fl
uo
re
sc
en
ce
 5
60
/5
90
 (×
1,
00
0)
DMSO
LPZ 10 µM
Rif
am
pic
in 
5 µ
M 
Mo
xifl
ox
ac
ine
 10
 µM
 
La
ns
op
raz
ole
 10
 µM
 
5-h
yd
rox
y-L
PZ
 50
 µM
 
Om
ep
raz
ole
 50
 µM
 
Pa
nto
pra
zo
le 
50
 µM
DM
SO
0
5
10
15
20
25
20
25
30
35
40
45
20 10 5 2.5 1.25 0.6
DM
SO
Rif
am
pic
in 
5 µ
M 
 LPZ concentration (µM)
MRC-5 lung fibroblasts
RAW264.7 macrophages
20 10 5 2.5 1.25 0.6
0
5
10
15
15
20
25
30
Fl
uo
re
sc
en
ce
 5
60
/5
90
 (×
1,
00
0)
(ho
st-
ce
ll s
ign
al)
DM
SO
Rif
am
pic
in 
5 µ
M 
 LPZ concentration (µM)
Fl
uo
re
sc
en
ce
 5
60
/5
90
 (×
1,
00
0)
(ho
st-
ce
ll s
ign
al)
Fl
uo
re
sc
en
ce
 4
80
/5
10
 (×
10
0)
(M
tb
-
EG
FP
)
Fl
uo
re
sc
en
ce
 4
80
/5
10
 (×
10
0)
(M
tb
-
EG
FP
)
Figure 1 | Lansoprazole (LPZ) protects from Mtb-induced cytolysis and reduces intracellular bacterial burden. (a) Protective activity of LPZ and other
drugs against Mtb-induced killing of MRC-5 lung ﬁbroblasts. Data are expressed as the mean±s.d. of three individual experiments. Viable ﬁbroblasts were
quantiﬁed using Prestoblue. (b) Dose response of LPZ in the ﬁbroblast survival assay using Mtb expressing GFP. Grey bars display host cell survival, green
bars quantify intracellular Mtb-GFP (mean±s.d. of three independent experiments; right y axes are truncated for better visualization). (c) Dose response of
LPZ in Mtb-infected RAW264.7 macrophages. Grey bars display macrophage survival, green bars quantify intracellular Mtb-GFP (mean±s.d. of 3
independent experiments; right y axes are truncated for better visualization). Growth of intracellular bacteria was inhibited with an IC50 of 2.2mM.
(d) Confocal microscopy of Mtb-GFP-infected RAW264.7 macrophages after treatment with LPZ (10mM) or vehicle (dimethyl sulfoxide (DMSO)).
Macrophage nuclei were stained with 40,6-diamidino-2-phenylindole (scale bar, 20mm).
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(Supplementary Fig. 7a,b)15. Inactivity against SS18b is most
likely due to upregulation of the cytochrome bd-oxidase that
replaces QcrB, thus avoiding the effect of inhibitors such as
LPZS16.
To visualize both the L176P mutation and the T313A
mutation, which confers IPA resistance, we modelled the
mycobacterial protein on the published QcrB structure of
Rhodobacter sphaeroides17. Both mutations localized to the
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Figure 2 | LPZS is a highly selective antituberculous drug with in vivo activity. (a) Intracellular ratio of LPZ (m/z 370.0834gmol 1) and its metabolite
(m/z 354.0884 gmol 1) determined by electrospray ionization quadrupole time-of-ﬂight mass spectrometry (ESI-Q-TOF-MS) over a 48-h period in MRC-
5 cells. Representative example of three individual experiments; the complete data set can be found in Supplementary Table 2. (b) ESI–MS mass spectra in
the range m/z 350–375 measured for experiments performed on the cell lysate of MRC-5 ﬁbroblasts exposed to LPZ (extracted ion chromatograms can be
found in Supplementary Fig. 4a,b). (c) ESI–MS spectrum at m/z 354.0884 corresponding to the LPZS standard in methanol. (d) Structures of LPZ and LPZS.
LPZS is missing the sulfoxide (red), which is essential for LPZ activity on the human proton pump. (e) LPZ/LPZS ratio determined by ESI-Q-TOF-MS over a
48-h period in 7H9 broth. Representative example of three individual experiments; the complete data set can be found in Supplementary Table 2. (f) Dose–
response curve of LPZS for Mtb grown in 7H9 broth (mean±s.d. of three individual experiments). (g) Survival of Mtb-infected MRC-5 ﬁbroblasts was
quantiﬁed at different concentrations of LPZS (mean±s.d. of three individual experiments). (h) Efﬁcacy of LPZS in the mouse model of acute tuberculosis.
Bacterial burden (c.f.u.) was determined in the lungs of four mice treated with the vehicle control (TPGS) or four mice treated with LPZS at 300mg kg 1
b.i.d. given by oral gavage (mean±s.d., Student’s t-test was used to compare groups).
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ubiquinol oxidation (Qp) site close to the Qp-inhibitor
stigmatellin, which was co-crystalized with the R. sphaeroides
protein (Fig. 4a). This indicates that both compounds target the
same QcrB-active site; however, L176P mutants remained
susceptible to several IPA compounds (Fig. 4b; Supplementary
Table 5). Conversely, growth of the highly IPA-resistant T313A
mutant was fully inhibited by LPZS, indicating distinct drug-
binding mechanisms for the two drugs (Fig. 4b).
Discussion
In this report, we present the combined use of host cell-based
drug screens and ex vivo pharmacokinetics, which identiﬁed a
novel class of antibiotic active against multi-drug-resistant Mtb.
Our ﬁndings have several important implications: ﬁrst of all
and most intriguingly, LPZS is a highly attractive and safe
antituberculous lead compound with in vivo activity that fails to
inhibit the gastric HþKþ -ATPase (Fig. 5). Future structure–
activity relationship studies will clearly beneﬁt from 40 years of
intense research on PPIs and their analogues. Substantial
amounts of in vitro and in vivo pharmacological data are
available for PPI metabolites, thereby providing a rich source for
repurposing these substituted benzimidazoles. Analogues with
antituberculous activity will have predictable side effects and
pharmacokinetic proﬁles, thereby accelerating translation into
pre-clinical and clinical development.
Furthermore, we have conﬁrmed QcrB as a highly speciﬁc and
druggable Mtb target capable of accommodating chemically
unrelated compounds with distinct binding mechanisms. The
commercially available cytochrome b inhibitor LPZS provides a
useful tool to further explore this multienzyme complex as a drug
target and to study the mycobacterial respiratory chain that is not
Table 1 | Activity of LPZS (in mM) against selected microorganisms.
Pathogen MIC90 day-7 REMA MIC90 day-7 OD600 MIC90 day-14 REMA MIC90 day-14 OD600
Mycobacterium tuberculosis H37Rv 1.13 1.02 1.71 1.34
Mycobacterium tuberculosis Erdman 1.21
Mycobacterium tuberculosis HN878 (Beijing strain) 1.74
Mycobacterium abcessus 2005-0524 4100
Mycobacterium avium 4100
Mycobacterium bolletii 1999-0888 4100
Mycobacterium marinum M 100
Mycobacterium massiliense 2005-0484 4100
Mycobacterium smegmatis mc2155 4100
Mycobacterium vaccae ATCC 15483 4100
Pseudomonas aeruginosa 4100
Pseudomonas putida 4100
Salmonella typhimurium 4100
Staphylococcus aureus 4100
Bacillus subtilis 4100
Candida albicans 4100
Corynebacterium diphtheriae 4100
Corynebacterium glutamicum 4100
Enterococcus faecalis 4100
Escherichia coli 4100
Listeria monocytogenes 4100
Micrococcus luteus 4100
LPZS, lansoprazole sulﬁde; MIC, minimal inhibitory concentration; REMA, resazurin reduction microplate assay.
Activity of LPZS is highly selective forMtb. The MIC of theMtb H37Rv strain was determined by REMA assays and OD600 measurements after 7 and 14 days of LPZS exposure. Both methods gave similar
results.
Table 2 | Activity of LPZS against drug-resistant clinical
isolates of Mtb.
Clinical isolate ID Resistance MIC90 (lM)
M. tuberculosis 59744 INH, RIF 0.78
M. tuberculosis MB3649 INH 1.37
M. tuberculosis MI1020 INH, STR 0.94
M. tuberculosis 43061 INH 0.49
M. tuberculosis 45776 INH 0.52
M. tuberculosis 49975 INH 1.06
INH, isoniazid; LPZS, lansoprazole sulﬁde; RIF, rifampicin; STR, streptomycin.
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Figure 3 | Evidence for LPZS targeting QcrB. (a) Dose response of LPZS
against wild-type Mtb, spontaneous-resistant mutants 1–3 and the
genetically engineered recombinant L176P strain (rMtb-L176P) (mean±s.d.
of triplicates). (b) Mutation in QcrB conferring LPZS resistance. The arrow
indicates the L176P mutation that confers resistance to LPZS. The
equivalent region of the human QcrB amino-acid sequence is aligned to the
Mtb sequence. (c) LPZS depletes ATP levels after 24 h of treatment
(mean±s.d. of three individual experiments). The ATPase inhibitor
bedaquiline and the cell-wall inhibitor isoniazid were used as controls. Drug
concentrations were 5 the MIC.
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well understood despite its key role in adaptive processes during
intracellular growth.
Several antimalarial drugs such as atovaquone bind the same
pocket of plasmodial cytochrome b, which indicates that targeting
the pathogen’s cytochrome bc1 complex is safe despite the
presence of human mitochondrial orthologues18. Intriguingly, a
recent report identiﬁed LPZ-like PPIs as potent inhibitors of
plasmodial growth only upon infection of metabolically active
liver cells19. The authors discuss metabolic transformation of the
compounds as a possible cause for their observation, although the
underlying mechanism or a drug target was not identiﬁed19. It is
very likely that intracellular sulfoxide reduction, as described in
our report, leads to antiplasmodial activity. Thus our ﬁndings can
improve the future control of both malaria and TB, two leading
causes of death.
The prodrug LPZ represents an excellent example of a valuable
hit compound in an existing library that was missed by
conventional drug screens. Using an innovative screen, we found
a new activity for an old drug that supports the notion that novel
screening platforms may uncover new antibiotics in old libraries1.
We provide evidence that intracellular assays are capable of
broadening the spectrum of existing small-molecule libraries by
identifying drugs that require the host cell environment for
their conversion to a bioactive metabolite. Up to 10% of
drugs approved worldwide can be classiﬁed as prodrugs that
are transformed by eukaryotic enzymes, such as esterases and
phosphatases, or by non-enzymatic reactions driven by
biochemical properties of the intracellular environment20. Using
host cells to transform approved drugs into derivatives with
antibacterial activity may render the drug inactive against its
original human target, as is the case for LPZ and LPZS (Fig. 5)9. A
substantial number of prodrugs can also be expected in small-
molecule libraries containing compounds of unknown function.
These molecules provide an untapped pool for antimicrobial drug
discovery. Our strategy of host-mediated prodrug activation is
generally applicable to other drug-resistant bacterial pathogens,
thereby enabling inhibitors with novel targets to be found in
compound libraries that have been interrogated previously in
standard phenotypic screens.
Methods
Drugs used in this study. LPZ, omeprazole and pantoprazole were purchased
from Sigma-Aldrich, LPZS and other LPZ analogues were purchased from Santa
Cruz biotechnology, Toronto Research Chemicals Inc. and Alfa Aeser. Q203 was
kindly provided by Kevin Pethe of the Institut Pasteur Korea. Other IPA com-
pounds were derived from a GlaxoSmithKline library kindly provided by Lluis
Ballell21.
Culture conditions of Mtb and eukaryotic cell lines. Mycobacterial strains were
routinely grown in Middlebrook 7H9 broth (supplemented with 0.2% glycerol,
10% albumin dextrose catalase (ADC) and 0.05% Tween-80) or 7H10 agar plates
(supplemented with 0.5% glycerol and 10% oleic ADC). MRC-5 human lung
ﬁbroblasts were provided by the Coriell Institute for Medical Research and grown
in MEM supplemented with 10% heat-inactivated fetal bovine serum, 1% non-
essential amino acids and 1mM sodium pyruvate. RAW264.7 macrophages derived
from the EPFL strain collection were grown in RPMI medium supplemented with
10% fetal bovine serum. Both cell lines were grown at 37 C with 5% CO2.
High-throughput drug screen and intracellular assays. Compounds of the
Prestwick chemical library were preplated into 384-well microplates (Corning) at a
concentration of 100mM in 5 ml of 5% dimethyl sulfoxide. MRC-5 cells grown to
late-log phase were harvested and seeded at 4,000 cells per well in a volume of 35 ml
using an automated microplate dispenser (multidrop combi, Thermo Scientiﬁc).
Cells were allowed to adhere for 3 h and then were infected with washed loga-
rithmic-phase Mtb Erdman cells at an MOI of 10 in 10 ml of MEM medium. Plates
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provide evidence that LPZS targets cytochrome bc1 (complex III) leading to
disruption of the mycobacterial respiratory chain and rapid ATP depletion.
Conversion of LPZS to the sulfenic acid intermediate necessary for
inactivation of the gastric HþKþ-ATPase is not possible, making LPZS a
highly selective lead compound for the tuberculosis drug pipeline.
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were sealed and incubated at 37 C in 5% CO2. After 72 h, the plates were left
at room temperature for 1 h and 5 ml of Prestoblue cell viability reagent (Life
Technologies) were added. After 1 h at room temperature, ﬂuorescence was
measured in a Tecan Inﬁnite M200 plate reader (excitation 570 nm and emission
590 nm). Mtb in infected macrophages or ﬁbroblasts was quantiﬁed using an Mtb
Erdman strain expressing EGFP and a Tecan plate reader (excitation 480 nm and
emission 510 nm).
For ﬂuorescence microscopy, RAW264.7 macrophages were seeded on round
9-mm coverslips in 24-well plates (105 cells per well). To quantify intracellular
Mtb, macrophages were infected at an MOI of 2 for 12 h. Cells were washed several
times to remove unphagocytosed bacteria and fresh medium containing
compounds or dimethyl sulfoxide was added. After incubation for 4 days, the cells
were washed and ﬁxed with 4% paraformaldehyde/PBS and stained with Dapi-
Fluoromount-G (Southern Biotech). Images were acquired on a Zeiss LSM 700
using ZEN imaging software and Fiji processing software. Resazurin reduction
microplate assays (REMAs) were performed in 7H9 broth using a starting OD600 of
0.0001, a 7-day (or 14 day) incubation period and a ﬁnal volume of 10% resazurin
(0.025% w/v). After incubation, ﬂuorescence of the resazurin metabolite resoruﬁn
was measured (excitation at 570 nm and emission at 590 nm, gain 80) using a
TECAN Inﬁnite M200. For OD600-based MIC determination, bacterial OD600 was
adjusted to 0.01 and bacteria were exposed to LPZS for 7 days followed by OD
readings. For reading after 14 days of exposure, initial OD600 was adjusted to
0.0001. Drug testing against streptomycin-starved 18b was performed as described
above for REMA assays using an SS18b culture maintained in 7H9 medium
without streptomycin for 2 weeks and a ﬁnal OD600 of 0.1 (ref. 15).
ATP-depletion assay and ADP quantiﬁcation. Log-phase Mtb cultures were
exposed to drugs for 24 h and mixed with BacTiter-Glo reagent (v/v 4:1) (Promega)
followed by incubation in the dark for 10min. Luminescence (relative light units,
RLUs) was read in a TECAN Inﬁnite M200. For ADP detection and calculation of
the ADP/ATP ratio, we exposed log-phase Mtb (OD600 of 0.01) to LPZS for 24 h in
a white 96-well plate. BacTiter-Glo reagent (v/v 4:1) was added and luminescence
was determined after 2min (RLUA). Plates were incubated in the dark for
15min and read again, which provided background ATP signals prior to ADP
measurements (RLUB). Five microlitre of an ADP-converting enzyme (Sigma
Alrich, MAK135E) were added, followed by a third measurement after 1min
of incubation (RLUC). The ADP/ATP ratio was calculated using the following
formula: ADP/ATP¼ (RLUCRLUB)/RLUA.
Culture conditions and REMA assay of other microorganisms. Mycobacterium
strains were grown in 7H9 broth (Difco) supplemented with Middlebrook ADC
enrichment, 0.2% glycerol, 0.05% Tween-80. Bacillus subtilis, Candida albicans,
Corynebacterium glutamicum, Escherichia coli, Micrococcus luteus, Pseudomonas
putida, Salmonella typhimurium and Staphylococcus aureus were grown in Luria
broth base (Sigma). C. diphtheriae, Enterococcus faecalis, Listeria monocytogenes
and P. aeruginosa were grown in brain heart infusion broth (Difco). Twofold serial
dilutions of each test compound were prepared in 96-well plates containing bac-
teria in a total volume of 100 ml and then incubated at 37 or 30 C (as required)
before addition of 10ml of 0.025% resazurin. After incubation, ﬂuorescence of the
resazurin metabolite resoruﬁn was determined as described above. Colony-forming
unit (c.f.u.) counts and checkerboard assays for drug combination studies were
performed using REMA assays and twofold serial dilutions of LPZS in combination
with the drugs mentioned in Supplementary Table 5. The fractional inhibitory
index (SFIC) was calculated as FIC (fractional inhibitory concentrations) of
compound Xþ FIC of compound Y to evaluate interaction proﬁles. The FIC was
calculated using the following formula: FIC (XþY)¼ [MIC of compound X in
combination with Y]/[MIC of X alone]. SFICs of r0.5 designate synergistic
activity and values 40.5 additive activity22,23.
Isolation and characterization of LPZS-resistant mutants. LPZS-resistant Mtb
H37Rv mutants were isolated by plating 109 c.f.u. on 7H10 agar containing 20 mM
of LPZS. Genomic DNA was isolated as described recently24. Whole-genome
sequencing was performed using Illumina technology with sequencing libraries
prepared using the NEBnext Ultra DNA kit (New England Biolabs). The resulting
genomic DNA fragment library was loaded on Illumina MiSeq Reagent Kit V3
cartridges and sequenced. All Illumina reads were right-trimmed to a length of 150
nucleotides to remove low-quality areas. Each sample was downsampled to 1.5-M
read pairs to even the genome coverage between samples. Analysis was done with
MIRA (version 4.0rc4) using the Mtb H37Rv genome (NC_000962.3) as reference.
The resulting SNP table was parsed in Excel to identify informative SNPs.
Recombineering method for target conﬁrmation. Mtb H37Rv carrying
plasmid pJV53 was grown to mid-log phase in 7H9 broth containing 25 mgml 1
kanamycin and exposed to 0.2% acetamide for 16 h. Competent cells were
co-transformed with 100 ng of single-stranded oligos (lagging and leading strand)
(50-CTCACTGCCTGACGACCTGCTGTCGGGACTCGGTCCGCGCGCGGCAC
TCTCGTCGATCACGCTGGGTATGC-30—for the L176P mutation) or (50-GGCG
GGCTCGCAGCCAGACTTCTACATGATGTGGGCCGAGGGTCTGGCCCGG
ATCTGGCCGCCGTGGGAG-30—for the T313A mutation) and pYUB412 (50 ng)
followed by plating on 7H10 agar plates containing 50 mgml 1 hygromycin. SNPs
in hygromycin-resistant clones were conﬁrmed by PCR and sequencing using
oligos 50-TGCTGATCACCGGCGTGTAT-30 and 50-AAGATGATCCCCGGCA
ACAG-30 for L176P or 50-TTCAAGTCCGGCGCATTTTT-30 and 50-TAGACGA
ACGGCGGCAGAAT-30 for T313A.
Ex vivo pharmacokinetics and ESI–MS. For intracellular drug quantiﬁcation,
20,000 MRC-5 cells were seeded in 96-well plates and exposed to 2 mM LPZ. At
given time points, cells were extensively washed with PBS and lysed with 0.1%
Triton X-100 in PBS and acetonitrile (1:1 ratio). After spinning at 15,000g at 4 C,
samples were shock-frozen in liquid nitrogen and stored at  80 C for MS.
Quantiﬁcation in 7H9 broth was performed with 500 nM of LPZ, acetonitrile was
added in a 1:1 ratio at given time points followed by spinning and shock freezing.
The UPLC separation was done on an Agilent 1290 Inﬁnity LC system including
the 1290 Inﬁnity LC system binary pump with an integrated degasser, the high-
performance autosampler and a thermostatted column compartment. Samples
(2 ml) were injected into a Zorbax Extend-C18 (2.1 50mm, 1.8 mm) analytical
column (Agilent Technologies) operated at 40 C, using H2O–HCOOH 0.1% and
CH3CN–HCOOH 0.1% as mobile phases A and B, respectively, (2–100% B in
5min) at a ﬂow rate of 0.4mlmin 1. All samples were injected in duplicate. The
UPLC system was interfaced with a 6530 Accurate-Mass Q-TOF LC/MS system
(Agilent Technologies). ESI–MS data were acquired in the positive ionization
mode, in the mass range m/z 100–1,000 (2 spectra s 1). Experimental parameters
were set as follows: fragmentor: 190V, Vcap: 3,500V, gas temperature: 300 C and
sheath gas temperature: 350 C. External calibration was carried out with a solution
of ESI_L (Agilent). Data were processed using MassHunter quantitative analysis
compliance software. Extracted ion chromatogram of ions at m/z 354.088 and
370.083 were integrated and quantiﬁed using external calibration of both LPZ and
LPZS spiked in the same matrix.
Mouse studies. For pharmacokinetic studies, female BALB/c mice (18–20 g) were
given 100mg kg 1 or 300mg kg 1 LPZS in 20% TPGS (D-a tocopheryl poly-
ethylene glycol 1,000 succinate) by gavage. At given time points, blood from three
mice was taken and, after spinning, serum was treated with acetonitrile (1:4 ratio).
After a second spin, supernatants were frozen for LC/MS experiments. For in vivo
efﬁcacy studies, mice were treated following the acute infection protocol of Rullas
et al.25 with some modiﬁcations. In brief, female BALB/c mice (18–20 g; 4 mice per
group) were aerosol infected with Mtb H37Rv and treated the following day with
300mg kg 1 LPZS b.i.d. by gavage for 9 days. The day after ﬁnal treatment, mice
were killed and serial dilutions of lung homogenates were plated on 7H10 agar
containing 10 mgml 1 cycloheximide and 25 mgml 1 ampicillin. Experiments
were approved by the Swiss Cantonal Veterinary Authority (authorization number
2218).
Statistical analysis. Student’s t-test was used throughout the paper to compare
two groups.
Protein structure prediction. QcrB (Rv2196) from M. tuberculosis was modelled
using the software iTasser (http://zhanglab.ccmb.med.umich.edu/I-TASSER/) and
the cytochrome bc1 structure from R. sphaeroides as template (PDB code 1QJY).
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